Chimeric Neurotoxin Domain Linking for Potency and Duration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for optimized chimeric neurotoxins with improved therapeutic properties, such as increased potency, safety, and duration of action, which are not adequately addressed by existing clostridial neurotoxins used in therapeutic and cosmetic treatments.
Innovation Solution
The design of chimeric neurotoxins involves covalently linking the LHN domain from a first neurotoxin with the HC domain from a second neurotoxin, ensuring the C-terminal residue of the LHN domain corresponds to the first amino acid of the 310 helix separating the LHN and HC domains in the first neurotoxin, and the N-terminal residue of the HC domain corresponds to the second amino acid of the 310 helix in the second neurotoxin, preserving the secondary structure and minimizing tertiary structure changes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If chimeric neurotoxins are designed by covalently linking LHN domain from one neurotoxin with HC domain from another neurotoxin, then potency and duration of action are improved, but manufacturing precision and structural integrity become more difficult to maintain
Solution Approach 1:
The chimeric neurotoxin is divided into distinct functional domains (LHN domain from first neurotoxin, HC domain from second neurotoxin) that are covalently linked. This segmentation allows each domain to contribute specific properties: the LHN domain provides potency and catalytic activity, while the HC domain provides targeting specificity and stability, thereby extending duration of action while maintaining manufacturability through modular design
Solution Approach 2:
The invention creates a composite protein structure by combining domains from different neurotoxin sources (e.g., botulinum neurotoxin and tetanus neurotoxin) into a single chimeric molecule. This composite structure integrates the high potency of botulinum LHN domains with the stability and long duration of action characteristics of tetanus HC domains, achieving enhanced therapeutic properties
2Stability of the object's composition
If the C-terminal residue of LHN domain and N-terminal residue of HC domain are precisely positioned at the 310 helix interface, then structural integrity and solubility are maintained, but design complexity increases
Solution Approach 1:
The invention specifies precise parameter constraints for the chimeric neurotoxin construction: the C-terminal residue of the LHN domain must correspond to the first amino acid of the 310 helix, and the N-terminal residue of the HC domain must correspond to the second amino acid of the 310 helix. This parameter control ensures proper secondary structure formation at the domain interface, maintaining structural integrity and solubility while providing clear design guidelines that manage complexity
3Ease of operation
If existing clostridial neurotoxins are used for therapeutic treatments, then simplicity of use is maintained, but potency and safety ratio are insufficient
Solution Approach 1:
The chimeric neurotoxin applies local quality optimization by selecting specific domains from different neurotoxin sources to confer localized functional improvements. The LHN domain provides high potency and catalytic efficiency, while the HC domain provides enhanced stability, reduced immunogenicity, and prolonged circulation time. This localized optimization of different protein regions achieves improved safety and efficacy while maintaining the overall simplicity of neurotoxin administration
Data Source
AI summary
The present invention relates to chimeric neurotoxins with enhanced properties and their use in therapy.